NMN
NMN, licence 80146212: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Nicotinamide Mononucleotide
- Licence holder
- Mitsubishi Corporation Life Science Limited
- NPN or DIN-HM
- 80146212
- Status
- Active licence
- Licence date
- 16 December 2025
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| 3-(Aminocarbonyl)-1-(5-O-phosphonato-bêta -D-ribofuranosyl)pyridinium | 250.0 mg | Not calculated |
Non-medicinal ingredients
Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18.0 Année(s) | minimum: 1.0 Capsule ; maximum: 4.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
(Source of NMN, which) helps to maintain blood NAD+ levels, to support cellular health. Helps to increase NAD+ levels, a cofactor in cellular energy metabolism. Nicotinamide mononucleotide (NMN) supplementation helps increase NAD+ level in blood for the maintenance of good health. Nicotinamide mononucleotide (NMN) supplementation helps maintain NAD+ level in blood for the maintenance of good health. Nicotinamide mononucleotide is a NAD+ precursor that helps maintain NAD+ levels in the body (that are broken down over time as we age) for the maintenance of good health. Helps to improve physical performance in low-resistance short-duration exercise (such as walking) in older aged adults. Source of (an) antioxidant(s)/Provides (an) antioxidant(s). Source of (an) antioxidant(s)/Provides (an) antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. A factor in the maintenance of good health. A factor in normal growth and development. Supports biological functions which play a key role in the maintenance of good health. Helps normal growth and development. Helps in energy metabolism/(and) tissue formation. Helps (to) maintain/support the body's ability to metabolize nutrients. NMN is a NAD+ precursor which is a factor in normal growth and development. NMN is a NAD+ precursor which helps to support biological functions which play a key role in the maintenance of good health. NMN is a NAD+ precursor which is an important cofactor in energy metabolism.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80146212
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.